The business services sector has outperformed, riding a wave of corporate demand for efficiency. But with economic sensitivity looming, we analyze two companies with robust models and one where caution may be warranted.
The banking sector has surged 12.5% in six months, outpacing the broader market. Yet, beneath the headline gains, selectivity is key. We analyze one bank with a unique value proposition poised for sustainable growth and flag two others where the risk-reward appears less compelling for investors.
Lyft's stock has experienced significant volatility, with recent gains failing to offset broader declines. As the company pushes its autonomous driving and European expansion narrative, investors are left weighing its premium valuation against a challenging competitive landscape and uncertain path to sustained profitability.
Citizens JMP reaffirms its bullish stance on Salesforce, citing the explosive growth of its AI platform Agentforce and strong enterprise adoption as key catalysts for sustained outperformance.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
The U.S. Federal Trade Commission has issued warnings to 42 prominent law firms, suggesting their diversity, equity, and inclusion hiring initiatives could violate antitrust laws by potentially restricting competition for talent.
Standex International reports consecutive quarters of record profitability, driven by strategic acquisitions and growth in electrical grid and aerospace markets, while navigating global trade uncertainties.
Sources indicate OpenAI is accelerating plans for a late-2026 public listing, a move that would place its massive cash burn and long road to profitability under intense investor scrutiny, potentially defining the next phase of the AI boom.
A Florida couple is suing their fertility clinic after discovering the baby girl born via IVF is not genetically related to them, sparking a complex legal and ethical battle over parentage and clinic accountability.
Secretary-General Antonio Guterres has issued a stark warning that the United Nations is at risk of running out of cash by July, citing a deepening funding crisis exacerbated by withheld U.S. contributions and systemic budgetary pressures.
The U.S. rig count saw a marginal increase this week, yet remains significantly below last year's levels as crude production dips and completions activity sends conflicting signals.
Oshkosh Corporation topped revenue expectations in its latest quarter, but profit fell short as tariffs and cost pressures squeezed margins. The specialty vehicle maker's 2026 outlook balances targeted growth in some segments against persistent challenges in construction markets.
Mid-cap companies offer a compelling blend of established operations and growth runway, but they navigate a perilous landscape between industry titans and agile disruptors. We examine three stocks where investor optimism may be overlooking critical challenges.
The third-quarter earnings season reveals a tale of two strategies in the property services sector. While Opendoor stumbles amid a major strategic shift, peers like Howard Hughes Holdings post surprising strength, highlighting the industry's uneven adaptation to a higher-rate environment.
Stablecoin rewards and the Clarity Act widen the divide between crypto and TradFi, according to people who spoke with the WSJ.
Weekly unemployment filings in New York state rose last week, contrasting with a slight national decline and highlighting regional economic disparities.
Specialty metals maker Carpenter Technology (CRS) posted record quarterly operating income and lifted its 2026 guidance, fueled by robust aerospace and defense demand. Despite the strong performance, its stock price has pulled back sharply, presenting a potential valuation disconnect for investors.
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
